The Stop CMV Act of 2025 adds a new section to the Public Health Service Act authorizing newborn screening for congenital Cytomegalovirus (CMV). It permits hospitals and other newborn-care entities to test infants for congenital CMV, directs state health executives to set testing standards and parent-notification procedures, and gives a federal advisory committee authority to step in if states do not act.
To support implementation the bill authorizes federal grant programs and research: HRSA grants flow to states to help entities administer tests; CDC cooperative agreements fund data systems and education; and NIH is directed to establish or expand research on screening methods, interventions, diagnostics, and vaccines. The bill also amends the Advisory Committee on Heritable Disorders in Newborns and Children to carry out related activities.
At a Glance
What It Does
The bill authorizes hospitals and newborn-care entities to perform congenital CMV testing for infants within the newborn period, while leaving testing optional rather than mandatory. It assigns primary implementation responsibility to state chief health officers to develop standards and parent-notification procedures and gives a federal advisory committee a fallback role if states fail to act.
Who It Affects
This applies to hospitals and health-care entities that care for newborns, state public health agencies responsible for newborn screening policy and surveillance, clinical laboratories that would perform CMV diagnostics, and federal agencies (HRSA, CDC, NIH, and the Advisory Committee) that provide funding, technical assistance, and oversight.
Why It Matters
If implemented, the bill creates the first explicit federal statutory framework for congenital CMV screening that links state-level policy, federal funding, and research. That combination can accelerate detection, data collection, and clinical research — but it also shifts practical and financial responsibilities to states, hospitals, and labs, which will influence how widely and quickly screening is adopted.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Stop CMV Act inserts a new statutory section that lets hospitals and other newborn-care providers administer tests for congenital CMV to infants in the newborn period. The bill uses permissive language: it authorizes testing rather than imposing a federal mandate.
Instead of a one-size-fits-all federal rule, it places primary authority with each State’s chief executive officer for health to prescribe standards and procedures for testing, recordkeeping, follow-up, and how results are communicated to parents or guardians.
The statute builds a safety valve: if a State has not adopted approved standards and procedures within a specified implementation period, the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children will prescribe standards the State may implement. The Advisory Committee also reviews and approves standards, considering practices in other States, existing newborn-screening procedures for other heritable disorders, and relevant scientific evidence.To help states and providers put testing into practice, the bill directs three streams of federal support.
HRSA is to award grants to States that have prescribed standards so states can distribute funds to hospitals and other entities to administer the tests. The CDC is authorized to provide grants or cooperative agreements to help states develop and improve congenital CMV data collection systems and to support education and training for clinicians, patients, and the public, including evidence-based web materials.
The NIH is directed to establish or expand research programs on screening technologies, intervention efficacy, diagnostics, prevention, treatment, and vaccine development; the statute signals NIH should use funds already available to it for those activities.Finally, the bill amends the Advisory Committee’s charter to add carrying out activities under the new CMV screening section, formalizing the committee’s role in standard-setting, review, and technical oversight related to congenital CMV screening and surveillance.
The Five Things You Need to Know
The bill authorizes testing for congenital CMV in infants who are 21 days of age or less (age window set by the Secretary).
Testing is permissive: hospitals and other newborn-care entities may administer tests — the statute does not impose a federal testing mandate on providers.
If a State fails to adopt approved testing standards within two years of enactment, the Advisory Committee on Heritable Disorders in Newborns and Children must prescribe standards that the State may implement.
The bill authorizes HRSA grant funding to States to distribute to entities administering tests and separately authorizes CDC grants/cooperative agreements for data systems and education; HRSA and CDC grant authorizations are tied to fiscal years 2026 and 2027.
The NIH is directed to establish or expand research programs on CMV screening, diagnostics, interventions, prevention, and vaccine development, and the bill explicitly directs NIH to use amounts available to it for those activities rather than creating a new appropriation stream.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Permission to test newborns for congenital CMV
This subsection authorizes each hospital or health-care entity caring for infants in the newborn period to administer, or cause to have administered, a test for congenital CMV. The provision is permissive — it creates legal authority to test without imposing a federal duty to test every newborn. Practically, that leaves adoption decisions to hospitals, providers, and states, and means uptake will depend on reimbursement, operational capacity, and state policies.
State standards, parent notification, and Advisory Committee fallback
Subsection (b) gives the chief executive health officer in each State authority to prescribe standards and procedures covering how tests are administered, how results are recorded and tracked, follow-up review processes, and educational activities. It also requires standards for how testing information is conveyed to parents or guardians. If a State has not issued standards approved by the Advisory Committee within two years of enactment, the Advisory Committee must step in and prescribe standards for that State to implement. The Advisory Committee’s review must consider other States’ practices, existing newborn-screening standards, and relevant scientific evidence, making it the technical gatekeeper for minimum acceptable practice where states do not act.
HRSA grants to States to support test administration
The Secretary, through HRSA, must award grants to States that have prescribed standards and procedures; those States in turn distribute funds to hospitals and entities to administer CMV tests. The statute authorizes appropriations "as may be necessary" for fiscal years 2026 and 2027 to carry out this HRSA grant program. That limited multiyear authorization creates a near-term funding window for implementation but does not set a permanent appropriation schedule or entitlement.
CDC cooperative agreements for surveillance, education, and training
This subsection directs CDC to award grants or enter cooperative agreements with States to build and improve congenital CMV data-collection systems and to provide technical assistance. It also funds education and training for providers and the public, including publishing evidence-based materials online. Like HRSA, CDC grant authority is linked to appropriations for fiscal years 2026 and 2027, emphasizing initial ramp-up support for surveillance and outreach.
NIH research mandate and Advisory Committee role expansion
The bill requires the NIH Director to establish or expand programs to research screening techniques, intervention efficacy, diagnostics, prevention and treatment approaches, and vaccine development for congenital CMV, and instructs NIH to use amounts available to the Director. Separately, the bill amends the Advisory Committee’s statutory duties to explicitly include carrying out activities under the new CMV screening section, formalizing the committee’s oversight and standard-setting role.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Infants and families—early identification of congenital CMV can enable timely monitoring, early interventions for hearing loss or developmental delays, and access to counseling and services that may improve long-term outcomes.
- State public health agencies—states that adopt standards gain federal grant funding and CDC technical assistance to build surveillance systems and public-education campaigns, strengthening newborn-screening portfolios.
- Clinical researchers and NIH-funded investigators—explicit NIH direction to expand CMV screening and treatment research channels more resources and institutional support for diagnostics, intervention trials, and vaccine work.
- Hospitals and pediatric providers that adopt screening—those institutions can access HRSA-distributed funds and CDC materials to operationalize testing and provider education, potentially improving clinical pathways for affected infants.
- Parent and patient advocacy groups—education, standardized reporting, and federal-backed surveillance improve data visibility and make advocacy and service planning more evidence-based.
Who Bears the Cost
- Hospitals and clinical laboratories—introducing CMV screening requires purchasing tests or reagents, changing workflows, staff training, and reporting systems; ongoing operational costs may outlast the initial federal grant window.
- State health departments—states must draft, adopt, and enforce standards, expand surveillance capacity, and run education campaigns; smaller or under-resourced states may face unfunded implementation burdens.
- Federal appropriations/taxpayers—the bill authorizes HRSA and CDC funding for two fiscal years and relies on NIH using available funds, which reallocates or requires appropriations at the federal level.
- Advisory Committee and federal agencies—the Advisory Committee gains new duties for standard review and fallback standard-setting, and CDC/HRSA must manage grant programs, increasing administrative workload.
- Insurers and payers—uncertainty about reimbursement for screening and follow-up services could lead to cost-shifting to payers and families if public funding lapses.
Key Issues
The Core Tension
The central tension is between early-detection public health benefits and the practical costs and variability that follow: the bill advances detection, data, and research while stopping short of a national mandate, which protects state flexibility but risks inconsistent access, uneven data, and a short-term funding window that may not be sufficient to sustain standardized screening and follow-up care.
The bill creates a federal framework while deliberately avoiding a universal federal mandate; that choice reduces federal overreach but almost guarantees a patchwork of state policies and uneven screening adoption. Because testing is permissive and rests on state standards, coverage, clinical uptake, and parental notification practices will likely vary.
The statute provides short-term federal funding authorizations for HRSA and CDC through two fiscal years and directs NIH to use available funds for research; it does not create an ongoing, dedicated appropriation, leaving long-term sustainability uncertain.
Operationally, the bill leaves important technical and programmatic questions unanswered. It does not specify approved testing modalities (for example, saliva vs urine PCR), thresholds for positive results, parental-consent requirements, or standardized follow-up clinical pathways for asymptomatic infants who screen positive.
Those technical details will determine false-positive/false-negative rates, lab capacity needs, and downstream clinical workload. The data-collection mandate raises privacy and interoperability issues: states will build or expand systems with varying data standards, complicating national surveillance and multicenter research.
Finally, the bill’s reliance on states to pass standards and on the Advisory Committee as a fallback raises legal and political questions about how prescriptive the Committee’s standards can be and how states must implement them without new ongoing federal funding.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.